Skip to main content

Table 1 Comparison of clinicopathologic features

From: Influence of cirrhosis on long-term prognosis after surgery in patients with combined hepatocellular-cholangiocarcinoma

Variables Cirrhosis
n = 91
Non- cirrhosis
n = 53
P-value
Sex (male/female), n 89/2 46/7 0.274
Age (years; mean ± SD) 53.2 ± 9.2 52.1 ± 8.1 0.463
Overweight (BMI 25.0-29.99 kg/m2), n (%) 15 (16.5) 10 (18.9) 0.716
Obesity (BMI ≥ 30 kg/m2), n (%) 3 (3.3) 2 (3.8) 0.880
Hypertension, n (%) 12 (13.2) 6 (11.3) 0.744
Diabetes mellitus, n (%) 10 (11.0) 4 (7.5) 0.501
Hepatitis B surface antigen, n (%) 79 (63.8) 22 (37.2) <0.001
Alcohol use, n (%) 24 (26.4) 5 (9.4) 0.015
Total bilirubin (μmol/L; mean ± SD) 17.8 ± 8.8 15.4 ± 4.1 0.090
Albumin (g/L; mean ± SD) 40.5 ± 5.3 41.2 ± 4.6 0.417
Aspartate aminotransferase (IU/L; mean ± SD) 51.2 ± 35.3 39.6 ± 22.3 0.021
Alanine aminotransferase (IU/L; mean ± SD) 54.5 ± 50.6 41.8 ± 36.7 0.043
Child-Pugh (A/B), n 85/6 53/0 0.056
Tumor diameter (cm; mean ± SD) 4.9 ± 2.5 6.7 ± 2.8 <0.001
Tumor number (St/Mt), n 82/9 46/7 0.541
Encapsulation, n (%) 34 (37.4) 15 (28.3) 0.268
Vascular invasion, n (%) 41 (45.1) 27 (50.9) 0.495
Bile duct invasion, n (%) 17 (18.7) 11(20.8) 0.762
Lymph node involvement, n (%) 12 (13.2) 8 (15.1) 0.750
Alpha-fetoprotein ≥ 20 ng/mL, n (%) 56 (61.5) 22 (41.5) 0.020
Carbohydrate antigen 19–9 ≥ 37 U/mL, n (%) 31 (34.1) 21 (39.6) 0.503
Carcinoembryogenic antigen ≥ 5 ng/mL, n (%) 7 (7.7) 3 (5.7) 0.644
  1. BMI body mass index; St single tumor; Mt multiple tumors